<?xml version='1.0' encoding='utf-8'?>
<document id="29134945"><sentence text="Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro." /><sentence text="Myrcludex B is a first-in-class virus entry inhibitor for patients with chronic hepatitis B or B/D infections" /><sentence text=" In patients it will be coadministered with drugs needed for the disease or comorbidities" /><sentence text=" We aimed to define the risk of drug-drug interactions by characterizing the influence of myrcludex B on relevant drug transporting and metabolizing enzymes in vitro"><entity charOffset="90-101" id="DDI-PubMed.29134945.s4.e0" text="myrcludex B" /></sentence><sentence text="" /><sentence text="Inhibition of P-glycoprotein (P-gp; ABCB1), breast cancer resistance protein (BCRP/ABCG2), and the organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1/SLCO1B1 and OATP1B3/SLCO1B3) was measured in cells over-expressing the respective transporter using fluorogenic substrates" /><sentence text=" Inhibition of cytochrome P450 enzymes (CYPs) was assessed with commercially available kits" /><sentence text=" mRNA induction of drug transporting and metabolizing enzymes was measured in LS180 cells after 4 days of treatment by quantitative real-time PCR" /><sentence text=" Pregnane X receptor (PXR) activation was assessed using a reporter-gene assay" /><sentence text="" /><sentence text="Whereas activities of P-gp and BCRP were not influenced by myrcludex B, OATP1B1 and OATP1B3 were specifically inhibited with a 50% inhibitory concentration (IC50) of 0" /><sentence text="5 and 8" /><sentence text="7 µM, respectively" /><sentence text=" Myrcludex B weakly inhibited all CYPs tested at concentrations ≥10 µM except CYP2D6, which was not inhibited at concentrations up to 2 µM"><entity charOffset="1-12" id="DDI-PubMed.29134945.s14.e0" text="Myrcludex B" /></sentence><sentence text=" Myrcludex B had no influence on mRNA expression of CYP1A1, CYP3A4, UGT1A3, ABCB1, ABCC2 and ABCG2, and on PXR activity" /><sentence text="" /><sentence text="Our in vitro study suggests that myrcludex B is not at major risk of acting as a perpetrator drug" /><sentence text=" A potential inhibition of the uptake transporters OATP1B1 and OATP1B3 and a previous clinical finding of potential CYP3A inhibition, requires further evaluation and should be carefully addressed in future trials" /><sentence text="" /></document>